Related Experiment Video
Updated: Jan 29, 2026

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Rationally Designed Dual Kinase Inhibitors for Management of Obstructive Sleep Apnea-A Computational Study
Kosi Gramatikoff1, Miroslav Stoykov2, Mario Milkov2
1Research Institute, Medical University "Prof. Dr. Paraskev Stoyanov", 55 Marin Drinov Str., 9002 Varna, Bulgaria.
Abstract:
Background/Objectives: Obstructive sleep apnea (OSA) affects approximately 1 billion adults worldwide with extensive comorbidities, including cardiovascular disease, metabolic disorders, and cognitive decline, yet pharmacological therapies remain limited. Conventional bottom-up omics approaches identify numerous genes overlapping with other diseases, hindering therapeutic translation. This study introduces a top-down, comorbidity-driven approach to identify actionable molecular targets and develop rational dual kinase inhibitors for OSA management. Methods: We implemented a five-tier modeling workflow: (1) comorbidity network analysis, (2) disease module identification through NetworkAnalyst, (3) mechanistic pathway reconstruction of the CK1δ-(HIF1A)-PINK1 signaling cascade, (4) molecular docking analysis of Nigella sativa alkaloids and reference inhibitors (IC261, PF-670462) against CK1δ (PDB: 3UYS) and PINK1 (PDB: 5OAT) using AutoDock Vina, and (5) rational design and computational validation of novel dual inhibitors (ICL, PFL) integrating pharmacophoric features from natural alkaloids and established kinase inhibitors. Results: Extensive network analysis revealed a discrete OSA disease module centered on two interconnected protein kinases-CK1δ and PINK1-that mechanistically bridge circadian disruption and neurodegeneration. Among natural alkaloids, Nigellidine showed strongest CK1δ binding (-8.0 kcal/mol) and Nigellicine strongest PINK1 binding (-8.6 kcal/mol). Rationally designed dual inhibitors demonstrated superior binding: ICL (-7.2 kcal/mol PINK1, -8.9 kcal/mol CK1δ) and PFL (-10.8 kcal/mol CK1δ, -11.2 kcal/mol PINK1), representing -2.6-2.8 kcal/mol improvements over reference compounds. Conclusions: This study establishes a comorbidity-driven translational framework identifying the CK1δ-PINK1 axis as a therapeutic target in OSA. The rationally designed dual inhibitors represent third-generation precision therapeutics addressing OSA's multi-dimensional pathophysiology, while the five-tier workflow provides a generalizable template for drug discovery in complex multimorbid diseases.
Insights
This study identifies the CK1δ-PINK1 signaling pathway as a key target for obstructive sleep apnea (OSA) drug discovery. Novel dual kinase inhibitors were rationally designed, offering a new precision therapeutic approach for OSA management.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Biology
Background:
- Obstructive sleep apnea (OSA) affects over a billion adults globally, presenting significant comorbidities like cardiovascular disease and cognitive decline.
- Current pharmacological treatments for OSA are limited, and traditional omics approaches face challenges in therapeutic translation due to gene overlap with other diseases.
- A novel top-down, comorbidity-driven strategy is proposed to identify actionable molecular targets for OSA.
Purpose of the Study:
- To identify molecular targets for OSA management using a comorbidity-driven approach.
- To develop rational dual kinase inhibitors for OSA by targeting the CK1δ-PINK1 signaling cascade.
- To establish a generalizable workflow for drug discovery in complex, multimorbid diseases.
Main Methods:
- A five-tier modeling workflow including comorbidity network analysis and disease module identification.
- Mechanistic pathway reconstruction of the CK1δ-(HIF1A)-PINK1 signaling cascade.
- Molecular docking of *Nigella sativa* alkaloids and reference inhibitors against CK1δ and PINK1, followed by rational design and computational validation of novel dual inhibitors.
Main Results:
- Network analysis identified a discrete OSA disease module involving CK1δ and PINK1, linking circadian disruption and neurodegeneration.
- Specific *Nigella sativa* alkaloids showed potent binding to CK1δ and PINK1.
- Rationally designed dual inhibitors (ICL, PFL) exhibited superior binding affinities compared to reference compounds, indicating enhanced therapeutic potential.
Conclusions:
- The CK1δ-PINK1 axis is validated as a therapeutic target for OSA through a comorbidity-driven translational framework.
- Rationally designed dual inhibitors represent advanced precision therapeutics for OSA's complex pathophysiology.
- The developed five-tier workflow offers a scalable template for discovering drugs targeting complex, multimorbid conditions.
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Design Example: Measuring Distance Between Two Points with Obstructions
Design Example: Traverse Angle Computations
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Design Example: Managing Concrete Workability
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment

